Can Ropinirole Cause Hyponatremia?
Ropinirole is not a recognized cause of hyponatremia based on FDA labeling and available clinical evidence. The FDA-approved prescribing information for ropinirole does not list hyponatremia as a known adverse effect, and the drug's primary documented electrolyte-related concerns involve orthostatic hypotension and syncope rather than sodium disturbances 1.
Evidence from FDA Drug Labeling
The comprehensive FDA labeling for ropinirole details numerous adverse effects and warnings but makes no mention of hyponatremia 1. The documented cardiovascular effects include:
- Syncope (occurring in 12% of early Parkinson's disease patients vs 1% placebo, and 1% of RLS patients vs 0.2% placebo) 1
- Orthostatic hypotension (reported in 0.8% of RLS patients on ropinirole vs 0.4% on placebo) 1
- Hypotension with bradycardia in some cases 1
The primary patient counseling points focus on sedation, orthostatic symptoms, hallucinations, and impulse control disorders—not electrolyte abnormalities 1.
Clinical Context and Mechanism
While comprehensive reviews of drug-induced hyponatremia identify multiple medication classes as culprits—including diuretics, antidepressants, anticonvulsants, antipsychotics, and certain newer agents like SGLT2 inhibitors and immune checkpoint inhibitors 2, 3, 4, 5—dopamine agonists like ropinirole are not mentioned among the established causes.
The pathophysiology of drug-induced hyponatremia typically involves:
- Syndrome of inappropriate antidiuresis (SIAD) 2, 3, 4
- Volume depletion from diuresis 2, 4
- Endocrine dysfunction 5
- Renal tubular effects 5
Ropinirole's mechanism as a dopamine D2/D3 receptor agonist does not align with these pathways 1.
Important Clinical Caveat
One case report documented orthostatic hypotension attributed to ropinirole in a 71-year-old man with multiple comorbidities, which led to volume depletion and acute kidney injury with elevated creatinine (3.6 mg/dL) and BUN (66 mg/dL) 6. However, this represented hypovolemic complications from orthostatic hypotension rather than primary hyponatremia. The patient's symptoms resolved after discontinuing ropinirole and addressing volume status 6.
Clinical Recommendation
If hyponatremia develops in a patient taking ropinirole, investigate alternative causes systematically 7:
- Assess volume status (hypovolemic, euvolemic, or hypervolemic) 8, 9, 7
- Measure plasma osmolality to confirm hypotonic hyponatremia 7
- Check urine osmolality and urine sodium concentration 8, 9, 7
- Review all concurrent medications, particularly diuretics, antidepressants, anticonvulsants, and antipsychotics 2, 3, 4
- Evaluate for SIAD, adrenal insufficiency, hypothyroidism, and renal dysfunction 8, 9, 10
- Consider whether ropinirole-induced orthostatic hypotension has led to secondary volume depletion requiring diuretic adjustment 6
Do not attribute hyponatremia to ropinirole without excluding established causes, as this may delay appropriate diagnosis and treatment of the true underlying etiology.